Berkshire Hathaway’s Pfizer PFE Stock Holding History

Berkshire Hathaway’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-3,912,216	Closed	-$136M	–	51
2020 Q3	$136M	Buy	+3,912,216	New	+$137M	0.06%	43

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Berkshire Hathaway's PFE Position: Q4 2020 in Review

Berkshire Hathaway sold out of Pfizer (PFE) in Q4 2020, closing a stake of 3,912,216 shares — an estimated $136M sold.

Berkshire Hathaway first reported a position in PFE in Q3 2020 and held it in 1 quarter. The position peaked at $136M in Q3 2020. 2,674 funds tracked by Wall St. Rank hold PFE as of Q4 2020.

Berkshire Hathaway reported no remaining Pfizer position as of Q4 2020 after selling out during the quarter.
Berkshire Hathaway sold 3,912,216 Pfizer shares in Q4 2020, an estimated $136M.
Berkshire Hathaway first reported a position in Pfizer in Q3 2020 and held it in 1 quarter.
Berkshire Hathaway's Pfizer position peaked at $136M in Q3 2020.
2,674 funds tracked by Wall St. Rank held Pfizer as of Q4 2020.

Based on Berkshire Hathaway's 13F filing for Q4 2020, filed 16 Feb 2021.